Short-term Guidance Under Pressure, but Order Recovery and Expanding EUV Inspection Demand Strengthen Medium-term Growth Expectations

Overview

Lasertec Corporation primarily provides photomask and related inspection and measurement systems based on applied optical technologies, with semiconductor-related products accounting for around 90% of sales. FY6/26 results were broadly in line with expectations, but FY6/27 earnings guidance was below market expectations, mainly due to changes in product mix and increased R&D and personnel investment. UBS believes this does not represent a fundamental deterioration in product profitability, and that order recovery, accelerated fab equipment deployment in the second half, and structural growth in EUV inspection demand will continue to support medium-term earnings upside.

Core views

First, FY6/26 sales were in line with consensus expectations, and operating profit was only slightly below expectations, while fourth-quarter semiconductor production equipment sales increased 65% QoQ to ¥43.4bn, indicating improved shipment momentum. Second, FY6/27 sales and operating profit guidance are ¥290bn and ¥125bn, respectively, both below consensus expectations, with the profit margin expected to decline by 2.6 percentage points, mainly due to product mix and growth investments. Third, ACTIS and MATRICS orders have recovered significantly, and management expects FY6/27 orders to reach ¥300–400bn. Fourth, increasing AI-driven logic and memory chip investment, together with applications in thin-particle inspection, curvilinear masks, and EUV pellicles, should support structural expansion in EUV inspection demand; although the Chinese market is affected by EUV export restrictions, DUV demand centered on MATRICS could still drive a doubling of orders.

Analysis framework

The report compares actual results, company guidance, and market consensus expectations, and adjusts FY6/27–FY6/29 earnings forecasts based on order backlog, product mix, fab deployment pace, and EUV technology trends; valuation uses an EV/EBITDA method based on FY6/28 earnings forecasts.

Methodology notes

• Earnings AnalysisActuals–Guidance–Consensus Comparison

  Assess earnings deviations and expectation gaps by comparing actual financial results, management guidance, and market consensus expectations.

  FY6/26 results were broadly in line with expectations, but FY6/27 operating profit guidance was clearly below consensus expectations; order growth and the medium-term demand outlook constitute positive revision factors.

• Earnings ForecastingOrder and Product Demand-driven Forecasting

  Project future revenue and profit based on orders, backlog, equipment deployment pace, and end-market technology demand.

  UBS raised its FY6/27–FY6/29 operating profit forecasts based on the recovery in ACTIS and MATRICS orders and the expansion of EUV inspection demand.

• Valuation methodsEV/EBITDA valuation

  Determine target valuation using a multiple of enterprise value relative to earnings before interest, taxes, depreciation, and amortization.

  The target price is based on FY6/28 earnings forecasts and 22x EV/EBITDA. Although the valuation multiple was lowered from the previous 25x, higher earnings forecasts lifted the target price to ¥47,200.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Lasertec Corporation (6920.T)

  Direct research subject

  Strengths

  Has core applied optical technologies in photomask and related inspection and measurement equipment; benefits from EUV adoption, AI-driven logic and memory investment, and recovery in ACTIS and MATRICS orders.

  Weaknesses

  FY6/27 profit guidance is below market expectations, and changes in product mix plus increased R&D and personnel investment will cause the operating margin to decline in the short term.

  Comparison

  FY6/26 actual results were broadly in line with expectations; FY6/27 guidance was weaker than consensus expectations, but UBS significantly raised its earnings forecasts for FY6/28 and FY6/29.

  Risks

  Competitors entering the AMPI market, major customers lowering capital expenditure plans, delays in ACTIS revenue recognition, and EUV export restrictions in the Chinese market.

Key data

• FY6/26 Sales¥230.5bnDown 8.3% YoY, broadly in line with consensus expectations.
• FY6/26 Operating Profit¥105.2bnDown 14.3% YoY, slightly below the consensus expectation of ¥106.2bn.
• Period-end Order Backlog¥322.9bnUp ¥7bn from the beginning of the fiscal year, mainly driven by the recovery in ACTIS and MATRICS orders.
• Fourth-quarter Semiconductor Production Equipment Sales¥43.4bnUp 65% QoQ.
• FY6/27 Company Sales Guidance¥290bnUp 26% YoY, slightly below the consensus expectation of ¥292.8bn.
• FY6/27 Company Operating Profit Guidance¥125bnBelow the consensus expectation of ¥139.6bn.
• FY6/27 Order Expectation¥300–400bnManagement's expected range, with a midpoint of ¥350bn.
• UBS FY6/27 Operating Profit Forecast¥137.0bnPrevious forecast was ¥134.7bn.
• UBS FY6/28 Operating Profit Forecast¥186.7bnPrevious forecast was ¥162.6bn.
• UBS FY6/29 Operating Profit Forecast¥219.0bnPrevious forecast was ¥191.0bn.
• Target Price¥47,200Previously ¥46,600, based on FY6/28 forecasts and 22x EV/EBITDA.

Impact & implications

In the short term, FY6/27 earnings guidance below consensus expectations may limit valuation expansion, and R&D and personnel investments will also depress margins. However, improving orders and backlog indicate that revenue visibility is strengthening. If fab deployment accelerates in the second half and AI-related logic, memory investment, and EUV inspection applications grow as expected, earnings after FY6/28 could be significantly higher than previous forecasts. The current target price implies less than 10% upside versus the market price, consistent with the Neutral rating.

Risks

• Competitors entering the AMPI market, weakening the company's technological and market position.
• Major customers reassessing or cutting investment plans, causing equipment orders and revenue to fall short of expectations.
• Delays in ACTIS sales recognition, affecting the revenue cadence and earnings realization.
• Changes in product mix and increased R&D and personnel investment may keep margins under pressure for longer than expected.
• The Chinese market continues to be affected by EUV equipment export restrictions.
• Slower-than-expected 2nm mass production or High-NA adoption could weaken medium- to long-term incremental demand.

What to watch

• Whether FY6/27 orders can reach management's expected range of ¥300–400bn.
• Whether the recovery in ACTIS and MATRICS orders can continue and translate into revenue.
• Second-half fab equipment deployment and A200 HIT introduction progress.
• Demand growth related to EUV thin-particle inspection, curvilinear masks, and EUV pellicles.
• Whether MATRICS orders for DUV applications in China can double.
• The actual impact of product mix, R&D, and personnel investment on operating margins.
• Progress in 2nm mass production and the pace of High-NA technology adoption.